

**PENDING CLAIMS**

1-5. Cancelled.

6. (Currently amended) A method of elevating white blood cell count in a mammal comprising:

- a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and
- b) administering said CLA composition to said mammal under conditions such that ~~the white blood cell CD4 and CD8 counts of the mammal is~~ are elevated.

7. Canceled.

8. (Previously presented) The method of Claim 6, wherein said CLA composition is administered orally.

9. (Previously presented) The method of Claim 6, wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid

10. (Previously presented) The method of Claim 6, wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

11. (Previously presented) The method of Claim 6, wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

12. (Currently amended) A method of ~~attenuating allergic reactions treating type I or IgE mediated hypersensitivity~~ in a mammal comprising:

- a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and
- b) administering said CLA composition to said mammal under conditions such that

said ~~allergic reactions are attenuated~~ type I or IgE mediated hypersensitivity is reduced.

13. (Canceled).

14. (Previously presented) The method of Claim 7, wherein said CLA composition is administered orally.

15. (Previously presented) The method of Claim 7, wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid

16. (Previously presented) The method of Claim 7 wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

17. (Previously presented) The method of Claim 7, wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.